{
    "id": 1262,
    "fullName": "BRCA2 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 inact mut indicates that this variant results in a loss of function of the Brca2 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "inact mut",
    "createDate": "08/05/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6860,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including one patient with prostate cancer (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5875,
                    "pubMedId": null,
                    "title": "First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors",
                    "url": "http://meetinglibrary.asco.org/content/111725-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20455,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 83.3% (25/30) and a RECIST objective response rate of 52.4% (11/21) in patients with castration-resistant prostate cancer harboring deleterious mutations or homozygous deletion of BRCA1/2 (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19646,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (POLO) that supported FDA approval, Lynparza (olaparib) maintenance therapy significantly improved median progression-free survival compared to placebo (7.4 vs 3.8 months, HR=0.53, p=0.004) in patients with metastatic pancreatic adenocarcinoma harboring deleterious or suspected deleterious germline BRCA mutations (PMID: 31157963; NCT02184195).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                },
                {
                    "id": 17385,
                    "pubMedId": 31157963,
                    "title": "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31157963"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6847,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5875,
                    "pubMedId": null,
                    "title": "First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors",
                    "url": "http://meetinglibrary.asco.org/content/111725-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20090,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zejula (niraparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring deleterious or suspected deleterious BRCA1/2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15446,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in improved time to next therapy or death (51.8 vs 15.1 mo, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial response after platinum-based chemotherapy (PMID: 30345884; NCT01844986).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1964,
                "name": "fallopian tube cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13319,
                    "pubMedId": 30345884,
                    "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30345884"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11132,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a deleterious or suspected deleterious germline BRCA mutation (PMID: 28578601; NCT02000622).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10614,
                    "pubMedId": 28578601,
                    "title": "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578601"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18819,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9867,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 5274,
                "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7723,
                    "pubMedId": null,
                    "title": "Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study",
                    "url": "https://cancerres.aacrjournals.org/content/77/4_Supplement/S2-05"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17384,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of two Phase II trials (ARIEL 2 and Study 10) that supported FDA approval, Rubraca (rucaparib) treatment resulted in an objective response rate of 54% (21/39) in high-grade ovarian cancer patients harboring deleterious BRCA1/2 mutations (PMID: 28751443).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10428,
                    "pubMedId": 28751443,
                    "title": "FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751443"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15466,
                    "pubMedId": null,
                    "title": "Rubraca (rucaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17386,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rubraca (rucaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring deleterious germline and/or somatic BRCA1/2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1825,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying a loss of function BRCA2 mutation (PMID: 21097693).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2236,
                    "pubMedId": 21097693,
                    "title": "Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21097693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13738,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines as recurrence therapy for ovarian cancer patients harboring deleterious BRCA1/2 germline mutations and as maintenance therapy for ovarian cancer patients harboring BRCA1/2 germline or somatic mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15447,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in improved time to next therapy or death (51.8 vs 15.1 mo, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial response after platinum-based chemotherapy (PMID: 30345884; NCT01844986).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13319,
                    "pubMedId": 30345884,
                    "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30345884"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2146,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring deleterious or suspected deleterious germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2644,
                    "pubMedId": 25366685,
                    "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25366685"
                },
                {
                    "id": 10799,
                    "pubMedId": 26187614,
                    "title": "FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26187614"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14475,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either deleterious or suspected deleterious mutant BRCA1 or BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11641,
                    "pubMedId": 28754483,
                    "title": "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28754483"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1054,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 770,
                    "pubMedId": 20609467,
                    "title": "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20609467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18820,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15061,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EMBRACA) that supported FDA approval, Talzenna (talazoparib) treatment resulted in significantly longer median progression-free survival (8.6 vs 5.6 months, HR=0.54, p<0.001), and higher objective response rate (62.6% vs 27.2%, OR=5.0, p<0.001) compared to standard chemotherapy in patients with advanced ERBB2 (HER2)-negative breast cancer harboring known deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2 (PMID: 30110579; NCT01945775).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12586,
                    "pubMedId": 30110579,
                    "title": "Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30110579"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15468,
                    "pubMedId": null,
                    "title": "Talzenna (talazoparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18825,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Platinol (cisplatin) is included in guidelines as systemic therapy for patients with triple-receptor negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6506,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E7449 inhibited proliferation of a BRCA2-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair mutations (PMID: 26513298).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 724,
                "therapyName": "E7449",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4121,
                    "pubMedId": 26513298,
                    "title": "E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26513298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a BRCA2-deficient breast cancer cell line resistant to Lynparza (olaparib) demonstrated sensitivity to treatment with AZD2461 in culture, resulting in reduced cell viability (PMID: 27550455).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 2542,
                "therapyName": "AZD2461",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6849,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 4283,
                "therapyName": "Cyclophosphamide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5876,
                    "pubMedId": 25589624,
                    "title": "Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25589624"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20173,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with pancreatic ductal adenocarcinoma harboring either a germline BRCA1, BRCA2, or PALB2 inactivating mutation demonstrated a response rate of 65.2% (15/23), a median progression-free survival of 9.7 months, a median overall survival of 16.4 months, and a disease control rate of 78.3% (18/23) when treated with a combination of Gemzar (gemcitabine), Platinol (cisplatin), and Veliparib (ABT-888) (PMID: 31976786).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 9283,
                "therapyName": "Cisplatin + Gemcitabine + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17721,
                    "pubMedId": 31976786,
                    "title": "Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31976786"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15445,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in improved time to next therapy or death (51.8 vs 15.1 mo, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial response after platinum-based chemotherapy (PMID: 30345884; NCT01844986).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1725,
                "name": "peritoneum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13319,
                    "pubMedId": 30345884,
                    "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30345884"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18823,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Paraplatin (carboplatin) is included in guidelines as systemic therapy for patients with triple-receptor negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 1092,
                "therapyName": "Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1615,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "RAD52 is proposed to act redundantly to the BRCA1-BRCA2-PALB2 pathway in homologous recombination (PMID: 22964643). Pancreatic cancer cells with a BRCA2 inactivating mutation were sensitive to an aptamer targeting Rad52, in contrast with cells with wild-type BRCA2, suggesting that Rad52 is a promising therapeutic target for inducing synthetic lethality in BRCA2-deficient cells (PMID: 23836560).",
            "molecularProfile": {
                "id": 2756,
                "profileName": "BRCA2 inact mut RAD52 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1662,
                    "pubMedId": 22964643,
                    "title": "RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22964643"
                },
                {
                    "id": 1666,
                    "pubMedId": 23836560,
                    "title": "Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836560"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17321,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in PSA decrease of at least 50% in 53% (9/17) of metastatic castrate-resistant prostate cancer patients, with 3 responders harboring germline frameshift BRCA2 mutations and somatic deletion of the other allele, and 2 others with homozygous BRCA2 alterations, and resulted in a 12-mo. PFS probability of 83.3% in patients with mutations in DNA damage repair genes, compared to 36.4% in patients without (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 32502,
                "profileName": "BRCA2 del BRCA2 inact mut"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1283,
            "profileName": "BRCA2 inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 3449,
                    "name": "PARP-1 Inhibitor",
                    "profileName": "BRCA2 inact mut"
                },
                {
                    "id": 33,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "BRCA2 inact mut"
                }
            ]
        },
        {
            "id": 2756,
            "profileName": "BRCA2 inact mut RAD52 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32502,
            "profileName": "BRCA2 del BRCA2 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}